Hengrui Pharma(SH:600276) Xin Lang Cai Jing·2025-12-04 08:17Group 1 - FTSE Russell announced quarterly adjustments to its China stock indices, including the FTSE China 50 Index, FTSE China A50 Index, and FTSE China A150 Index, effective from December 22 [1][2] - The FTSE China 50 Index will include three new companies: China Hongqiao, CATL, and Heng Rui Medicine, while removing Citic Securities, Great Wall Motors, and Li Auto [1] - The reserve list for the FTSE China 50 Index includes China Aluminum, Hansoh Pharmaceutical, Huatai Securities, JD Health, and Xinhua Insurance [1] Group 2 - The FTSE China A50 Index will add Luoyang Molybdenum and Sungrow Power, while deleting Jiangsu Bank and SF Holding [2] - The reserve list for the FTSE China A50 Index includes Jiangsu Bank, SF Holding, Silergy, Shenghong Technology, and Wanhua Chemical [2] - FTSE Russell, part of the London Stock Exchange Group, provides indices and data solutions for global institutional investors, reflecting changes in market capitalization and liquidity in the Chinese stock market [2] Group 3 - UBS Securities analyst Meng Lei forecasts that the overall A-share profit growth will rise from 6% this year to 8% in 2026, driven by nominal GDP growth and narrowing PPI declines [4] - JPMorgan projects the CSI 300 Index to reach a target of 5200 points by the end of 2026, corresponding to a 15% year-on-year increase in earnings per share [4] - JPMorgan's strategists believe the probability of a significant rise in the Chinese stock market next year is higher than the risk of a major downturn, citing multiple positive incremental drivers [4]